GET DAILY SIGNALSNiagen Bioscience (NAGE) Slides -21% Over 30 Days as Competition and Estimate Revisions Mount
Key Takeaways
- NAGE shares have fallen roughly 21% over the last 30 days, sliding from about $3.05 to near $2.42 and trading close to their 52-week low.
- Over the last quarter, the stock has declined approximately 25%, extending a broader multi-month downtrend despite a debt-free balance sheet.
- The pullback has been amplified by downward analyst estimate revisions for fiscal 2026 following softer second-quarter profitability.
- Rising marketing spend and intensifying competition from NMN and other NAD+ precursor products have pressured near-term margins and sentiment.
- Positive catalysts, including a planned Mass General Brigham healthy-aging trial and new skincare and at-home injection launches, have not yet offset the selling pressure.
- Analysts still carry a consensus Strong Buy rating, with a 12-month price target around $12 that sits well above recent trading levels.
- For more detail, explore NAGE's Price Targets, Earnings, and Forecast pages.
- Traders looking for data-driven ideas can also explore Trending AI Robots.
Niagen Bioscience (NAGE) Company Overview and Market Position
Niagen Bioscience, Inc. (NAGE), formerly known as ChromaDex Corporation, is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging. Its core product, Tru Niagen, contains the company's patented form of nicotinamide riboside (NR), a precursor that supports NAD+ production in the body. The company positions Tru Niagen as a leading NAD+-boosting oral supplement and has expanded into pharmaceutical-grade intravenous and injectable products through its Niagen Plus line, as well as a newly launched Tru Niagen Skincare category.
The business operates across consumer products, ingredients, and pharmaceutical segments. Through its wholly owned subsidiary NAD Pharmaceuticals Corp., the company is researching NB4168, a differentiated molecule aimed at rare genetic and accelerated-aging diseases. I follow NAGE for its leadership in the NAD+ supplement market, its patent-protected ingredient portfolio, and its optionality in the longevity and rare-disease therapeutic space. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Niagen Bioscience (NAGE) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, NAGE shares have declined roughly 21%, moving from a closing price near $3.05 in late September to about $2.42 in recent trading. The stock now sits just above its 52-week low, reflecting sustained selling pressure across the period.
The trend is even more pronounced over the last quarter, where the stock has fallen approximately 25% from levels around $3.23 in late July. The most significant single-day move occurred after the company's second-quarter earnings report, when shares dropped sharply amid softer profitability and downward estimate revisions. The combination of a weak 30-day performance and a steeper quarterly decline indicates that the stock remains in a clear downtrend rather than experiencing a short-lived correction.
What Drove NAGE Stock Price in the Last 30 Days
Several verified factors contributed to the recent decline. Analyst estimate revisions have been a recurring headwind. In mid-October, consensus fiscal 2026 earnings-per-share estimates were reduced further, following earlier cuts in August that lowered revenue and EPS forecasts. These downward revisions have reinforced negative sentiment even as the company continued to announce operational developments.
On the fundamentals side, second-quarter 2026 results reported in early August showed earnings of $0.01 per share, down from $0.046 a year earlier, and net income that fell roughly 73% year over year. Higher sales and marketing spending, along with softer ingredient-segment revenue, compressed profitability and prompted the initial wave of estimate reductions that carried into the following weeks.
Competitive pressure has also weighed on the stock. Management has noted a growing number of NMN and other NAD-related products entering the market, which has increased advertising costs and added pricing pressure in certain channels. Meanwhile, positive announcements during the period, including a start-up agreement with Mass General Brigham to plan a large healthy-aging clinical trial and the launch of new skincare and at-home injection products, provided only limited offset against the broader negative trend.
What Drove NAGE Stock Performance Over the Last Quarter
The quarterly decline reflects a broader repricing of the company's near-term growth outlook. After a period of elevated expectations around the NAD+ and longevity categories, investors have reassessed the company's profitability trajectory in light of rising competition and increased investment in newer growth initiatives such as injectables, skincare, and international expansion.
Although the company maintains a debt-free balance sheet and reported positive net income in its most recent fiscal year, the market has focused on margin compression and the slower conversion of new product lines into earnings. Analyst target-price adjustments and consensus estimate cuts during the quarter reinforced a more cautious stance, even as the long-term pipeline story around NB4168 and pharmaceutical applications remained intact. The result has been a sustained drift lower in the share price rather than a single-event-driven decline.
NAGE Stock Forecast Drivers: What Investors Should Watch Next
Investors monitoring NAGE should watch several key catalysts in the near term. The company is scheduled to report third-quarter 2026 financial results in early November, and guidance updates, revenue trends, and margin commentary will be closely scrutinized given recent estimate revisions. Progress on the Niagen Plus injectable and IV business, the ramp of the new skincare category, and any updates on the Mass General Brigham healthy-aging trial represent important operational signals.
Competitive dynamics in the NAD+ precursor market, including pricing and marketing costs associated with NMN alternatives, remain a key risk. Regulatory developments affecting dietary supplement claims and NAD-related ingredients could also influence demand. Longer term, clinical milestones for NB4168 and the company's rare-disease program represent the most significant potential value drivers, though these carry substantial execution and timing uncertainty. As with any investment, the outlook should be evaluated against the company's actual reported results rather than projections alone. I’m watching this closely as the next earnings release approaches.
Exploring AI Tools for Stock Analysis
When I need a systematic way to review trading ideas across many tickers, I turn to Tickeron’s AI Trading Bots. The platform offers a range of strategies that can complement fundamental research, especially in sectors like biotech where volatility is common. It is one of several resources I use to cross-check patterns and signals before forming a view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
NAGE's RSI Oscillator slumps oversold zone
The RSI Indicator for NAGE moved into overbought territory on October 23, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAGE advanced for three days, in 189 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
NAGE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NAGE as a result. In 87 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for NAGE turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAGE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for NAGE entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.330) is normal, around the industry mean (1.672). P/E Ratio (12.150) is within average values for comparable stocks, (6.468). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.056) among similar stocks. P/S Ratio (1.976) is also within normal values, averaging (4.925).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. NAGE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NAGE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary-based ingredient technologies
Industry FoodMajorDiversified
Advertisement